Home » Newsletters » BioWorld Science

BioWorld Science

June 11, 2013

View Archived Issues

Novel NOTCH3 gene mutation linked to CADASIL

Biomarkers identified for 90-day mortality after intracerebral hemorrhage

Blood pressure-lowering activity demonstrated for ARA-290

LGX-818 shows initial promise in solid tumors and melanoma

Zebrafish model/computational screening to accelerate drug discovery

The discovery of a first-in-class inhibitor of a major human oxidative stress pathway

PBI-4050 demonstrates promising antifibrotic properties in vivo

Genotype determines response to butyrate in patients with congenital chloride diarrhea

TissueGene-C therapy evaluated in patients with knee osteoarthritis

AVEO Oncology receives complete response letter for tivozanib NDA

BioLineRx enters collaboration with Jiangsu Chia-tai Tianqing Pharmaceutical

Concert Pharmaceuticals begins phase I trial of CTP-354

Discovery Labs responds to FDA request for clarification regarding Surfaxin specifications

Dynavax reports on FDA meeting for Heplisav

HemaQuest Pharmaceuticals completes enrollment in phase IIb HQK-1001 study

Neumedicines receives BARDA award for HemaMax

Centaurus BioPharma presents novel B-raf inhibitors

Trigemina begins phase II trial of TI-001 in chronic migraine

Seattle Genetics begins phase I/II trial of Adcetris in combination with bendamustine

Xenon Pharmaceuticals licenses XEN-701 from Isis Pharmaceuticals

Chinese team patents new EGFR inhibitors for cancer

Heptares Therapeutics designs novel M1 receptor agonists

New agents for the treatment of Coxsackie viral infections disclosed by Chinese group

KBP BioSciences presents new DP2 receptor antagonists

Global alliance initiated to share genomic and clinical data

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.